Site-Selective Functionalized PD-1 Mutant for a Modular Immunological Activity against Cancer Cells

[Image: see text] Targeting immune checkpoints is a well-established strategy in cancer therapy, and antibodies blocking PD-1/PD-L1 interactions to restore the immunological activity against cancer cells have been clinically validated. High-affinity mutants of the PD-1 ectodomain have recently been...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallarini, Silvia, Cerofolini, Linda, Salobehaj, Maria, Rizzo, Domenico, Gheorghita, Giulia Roxana, Licciardi, Giulia, Capialbi, Daniela Eloisa, Zullo, Valerio, Sodini, Andrea, Nativi, Cristina, Fragai, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646970/
https://www.ncbi.nlm.nih.gov/pubmed/37902625
http://dx.doi.org/10.1021/acs.biomac.3c00893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646970/
https://www.ncbi.nlm.nih.gov/pubmed/37902625
http://dx.doi.org/10.1021/acs.biomac.3c00893

Ejemplares similares